Trevena ditches $86M IPO pitch; EU signs off on Roche's Kadcyla;

@FierceBiotech: Clovis bets up to $420M on targeted cancer drug. News | Follow @FierceBiotech

@JohnCFierce: Great talk with Missouri Bio and KansasBio today. About half read Fierce on their cell phones. New day and new media. | Follow @JohnCFierce

@DamianFierce: Meet Rebecca Friend, publisher of the FierceBiotech family of publications. More | Follow @DamianFierce

@EmilyMFierce: News about Art Levinson's Calico breaks on... Google+? Story | Follow @EmilyMFierce

> Trevena is the latest biotech hopeful to postpone plans for an IPO, pulling the plug on an $86 million offering. News

> Aeterna Zentaris ($AEZS) is raising $15.1 million in a stock sale to fund the development of AEZS-108, a breast and prostate cancer drug now in Phase II. More

> In one-year results, AMG 145, Amgen's ($AMGN) PCSK9 inhibitor, reduced LDL cholesterol by 52% compared to standard of care. Release

> The EU approved Roche's ($RHHBY) HER2-targeting cancer drug Kadcyla, which means another $5 million milestone for partner and antibody-drug conjugate mainstay ImmunoGen ($IMGN). Item

Medical Device News

@FierceMedDev: ResMed wins German court injunction against two respiratory device patent rivals. More | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B settlement addresses thousands of lawsuits over faulty metal hip implants but many will remain in play. Story | Follow @MarkHFierce

> Qiagen TB test gains Chinese regulatory approval. Article

> GenomeDx Biosciences seals multiple insurance deals for prostate cancer Dx. News

> Next Bard vaginal mesh trial set for December; settlement rumors remain. Report

Pharma News

@FiercePharma: Best-read new news Tuesday: Can Teva find a partner to save it from itself? Story | Follow @FiercePharma

@EricPFierce: GSK continues to lead with continuous processing. Will use technology at $136.5 million plant in India. More | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Ex-Teva chief Jeremy Levin to MBA grads: Anyone have a job for me? Story

> Daiichi clot-fighter aces study, but can it compete with Pradaxa, Xarelto and Eliquis? Article

Drug Delivery News

@MichaelGFierce: Delivery guru Robert Langer discusses nanomeds, up-and-coming ventures, new frontiers. Editor's corner | Follow @MichaelGFierce

> Unilife signs $80M deal to supply Hikma with prefilled syringes. Story

> FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. Article

> Svelte begins pivotal trial for drug-eluting stent. Report

> Study: Genes delivered directly to heart stymie heart failure. More

> Dual-wave approach clears path for cancer drug delivery. Story

> Oramed wins European patent for insulin pill tech. Item

Diagnostics News

> GenapSys nails down $37M to advance next-generation gene sequencing tech. Article

> Trovagene pledges results, in part, from cancer urine test launch. Report

> Houston Methodist-led team shows potential of early breast cancer blood Dx. More

> Atossa makes headway in getting breast cancer test back to market. Article

> FDA OKs 4 Illumina next-generation sequencing devices. Report

> Johns Hopkins approach shows promise in early dementia diagnosis. Item

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.